202 CoV
Alternative Names: 202-CoV; Recombinant SARS-CoV-2 Vaccine - Shanghai Zerun Biotechnology; ZR-202-CoVLatest Information Update: 06 Mar 2023
At a glance
- Originator Shanghai Zerun Biotechnology Co
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 06 Mar 2023 Shanghai Zerun Biotechnology completes a phase II trial in COVID-2019 infections (Prevention) in China (IM) prior to February 2023 (Shanghai Zerun Biotechnology Co pipeline, February 2023) (NCT04990544)
- 02 Jun 2022 Phase-I/II clinical trials in COVID-2019 infections (Prevention, in adults) in Mali (IM) (NCT05490108)
- 18 Jan 2022 Shanghai Zerun Biotechnology initiates a phase I/II clinical trial in COVID-2019 infections (Prevention) in China (IM) (NCT05313022)